{
    "clinical_study": {
        "@rank": "117806", 
        "arm_group": [
            {
                "arm_group_label": "Part A: Lu AF35700", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part B: Lu AF35700", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma\n      concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu\n      AF35700"
        }, 
        "brief_title": "D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound", 
        "condition": "Healthy Men", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy young men >=25 and <=45 years of age with a Body Mass Index (BMI) >=18.5\n             kg/m2 and <=30 kg/m2.\n\n        Other protocol-defined Inclusion and Exclusion criteria may apply."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093169", 
            "org_study_id": "15868A", 
            "secondary_id": "2013-004283-61"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A: Lu AF35700", 
                "description": "One 30 mg single dose for one day; orally", 
                "intervention_name": "Part A: Lu AF35700", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B: Lu AF35700", 
                "description": "Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally", 
                "intervention_name": "Part B: Lu AF35700", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dopamine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "GB801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Relationship between plasma concentrations and pharmacodynamic (PD) measures specified as binding potential at each scanning time point", 
                "safety_issue": "No", 
                "time_frame": "Up to 172 hours after dosing"
            }, 
            {
                "measure": "Relationship between plasma concentrations and PD measures specified as plasma concentrations of Lu AF35700, Lu AF36152 and Lu AF35700 + Lu AF36152 at each scanning time point", 
                "safety_issue": "No", 
                "time_frame": "Up to 172 hours after dosing"
            }, 
            {
                "measure": "Relationship between plasma concentrations and PD measures specified as occupancy in relation to plasma concentrations of Lu AF35700, Lu AF36152 and Lu AF35700 + Lu AF36152, respectively", 
                "safety_issue": "No", 
                "time_frame": "Up to 172 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093169"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Columbia Suicide Severity Rating Scale (C-SSRS) (Part B only)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Area under the curve (AUC), maximum observed concentration (Cmax), oral clearance (CL/F), and apparent elimination half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Up to 168 hours after dosing"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}